07:00 , Sep 29, 2016 |  BC Innovations  |  Targets & Mechanisms

Hitting for the cycle

Driven by the need for antimalarial drugs that hit all stages of the life cycle of the malaria parasite, a group at the Broad Institute of MIT and Harvard has constructed and screened a diverse...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Cipargamin: Phase II data

An open-label, Thai Phase II trial in 21 adults with uncomplicated Plasmodium vivax or P. falciparum malaria, including patients with resistant infections, showed that once-daily 30 mg oral KAE609 for 3 days met the primary...
00:41 , Aug 1, 2014 |  BC Extra  |  Clinical News

Novartis reports Phase II data for malaria compound

Novartis AG (NYSE:NVS; SIX:NOVN) said once-daily oral KAE609 for three days led to a median parasite clearance time, the primary endpoint, of 12 hours in an open-label Phase II trial to treat malaria. The Thai...
07:00 , Sep 27, 2012 |  BC Innovations  |  Tools & Techniques

Humanizing malaria mice

U.S. researchers have developed the first mouse model that recapitulates the human stages of the malarial parasite Plasmodium falciparum life cycle in one animal. 1 The academics plan to make additional modifications to the mice...
07:00 , Oct 7, 2010 |  BC Innovations  |  Cover Story

A new lead in malaria

A consortium of researchers led by the Novartis Institute for Tropical Diseases has identified a potent new class of antimalarials that could provide a much needed safeguard against parasites resistant to the largely artemisinin-based armamentarium...
07:00 , Sep 30, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Not applicable An in vitro and mouse study suggests that a spiroindolone compound may help treat malaria. In a range of drug-sensitive and...